May 14, 2019– Drug-industry consultant Adam Fein has released his annual analysis of the 340B program, painting an incomplete picture of the size and scope of the program. Fein claims in his Drug Channels blog that the 340B program “accounts for at least 7-to-8 percent of the total U.S. drug market […] yet hospitals’ charity care has dropped amid 340B program’s growth.” Not … [Read more...]
Drug companies answer scrutiny with more lobbying dollars
May 2, 2019— With its pricing practices under a congressional microscope, the pharmaceutical industry’s top trade group spent nearly $10 million on lobbying expenditures in the first three months of this year. That figure is on top of additional millions spent by some of the individual companies that have received the most attention recently in the drug pricing … [Read more...]
A Healthy Dose of Sunlight for Drug Companies
April 1, 2019— Today is a very good day for safety-net hospitals and the patients in need who rely on them. After nine long years of delay and preparation, the federal government today launched a new secure website. The site will provide hospitals, clinics, and health centers participating in the 340B drug pricing program with information on the maximum amount – or ceiling … [Read more...]
340B Advocates Meet in San Diego
February 5, 2019— Hundreds of pharmacists, 340B program directors, and other patient advocates convened in San Diego last week for the 15th Annual 340B Coalition Winter Conference, the largest such gathering to date. The event gave safety-net hospitals, community health centers, Ryan White clinics, and other safety-net providers a chance to discuss the latest developments in … [Read more...]
Hits & Misses: 340B Commentary Gets Some Things Right But Misses on Others
November 28, 2018— In a recent commentary published in the Journal of the American Medical Association (JAMA), authors Peter Bach of Memorial Sloan Kettering Cancer Center and Rachel Sachs of Washington University in St. Louis call for an alternative financial mechanism for the 340B program, claiming the 340B program has resulted in market distortions and shifts in physician … [Read more...]
Busy times for 340B in Washington
November 19, 2018—The midterm elections were not the only source of Washington-related news in recent weeks with implications for the health care system. When it comes to 340B, several key events occurred in the days leading up to Election Day that might have longer-lasting implications for the program than the makeup of the 116th Congress. White House thinks globally on … [Read more...]
Death, Taxes…and Drug Price Increases
July 6, 2018—There’s new evidence that pharmaceutical manufacturers have not gotten the message that the Trump administration and the American public want an end to rising drug prices. Research documenting a host of drug price increases in June and July above the rate of inflation could complicate the Trump administration’s advocacy for its drug pricing blueprint, which … [Read more...]